



## Financial Tear Sheet

### Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

AVEO Oncology  
Investor Relations  
Phone: 617-588-1960  
E-mail:  
[ir@aveooncology.com](mailto:ir@aveooncology.com)

### Stock Performance

#### AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$3.44
Change (%)	▼ 0.16 (4.44%)
Volume	3,907,775
52 Week Low	\$0.50
Market Cap	\$406,978,901
Rolling EPS	-0.58
PE Ratio	N/A

Shares Outstanding 118,307,820

Data as of 10/16/17 4:00 p.m. ET



### Recent Headlines

10/16/17  
AVEO Oncology Announces Phase 1 Results from TiNivo Study to be Presented at the 16th International Kidney Cancer Symposium

10/05/17  
AVEO Oncology Announces Completion of TIVO-3 Study Futility Analysis with No Changes to Study Protocol

09/20/17  
AVEO Oncology and EUSA Pharma Announce TiNivo Combination Study Opt-in

### Events

There are currently no events scheduled.

## SEC Filings

### FILING DATE FORM

08/21/17	4
08/17/17	8-K
08/10/17	8-K
08/09/17	8-K

Powered By **EDGAR** Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed